Qiagen (NYSE:QGEN) Issues FY 2024 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.160- for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of 2.160.

Qiagen Stock Down 0.2 %

QGEN traded down $0.09 on Friday, hitting $45.42. 847,455 shares of the company were exchanged, compared to its average volume of 1,245,056. Qiagen has a twelve month low of $34.74 and a twelve month high of $46.55. The company has a market cap of $10.36 billion, a price-to-earnings ratio of 30.46, a price-to-earnings-growth ratio of 3.19 and a beta of 0.40. The company has a current ratio of 1.77, a quick ratio of 1.45 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $42.85 and a two-hundred day moving average price of $43.04.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. The company’s revenue was down .2% compared to the same quarter last year. On average, equities analysts predict that Qiagen will post 2.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Stifel Nicolaus dropped their target price on shares of Qiagen from $55.00 to $45.00 and set a hold rating on the stock in a research report on Wednesday, May 1st. Robert W. Baird boosted their target price on Qiagen from $49.00 to $52.00 and gave the company an outperform rating in a report on Friday, August 2nd. Wolfe Research raised shares of Qiagen from a peer perform rating to an outperform rating and set a $50.00 price target for the company in a report on Thursday, June 27th. Finally, JPMorgan Chase & Co. increased their price objective on Qiagen from $52.00 to $54.00 and gave the stock an overweight rating in a research report on Tuesday, June 18th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Qiagen presently has an average rating of Moderate Buy and a consensus price target of $51.10.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.